Alan Heller Net Worth

The estimated Net Worth of Alan L Heller is at least $572 mil dollars as of 8 November 2018. Mr. Heller owns over 43,478 units of Neos Therapeutics Inc stock worth over $486,871 and over the last 9 years he sold NEOS stock worth over $0. In addition, he makes $85,500 as Independent Chairman of the Board at Neos Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Heller NEOS stock SEC Form 4 insiders trading

Alan has made over 3 trades of the Neos Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 43,478 units of NEOS stock worth $99,999 on 8 November 2018.

The largest trade he's ever made was buying 43,478 units of Neos Therapeutics Inc stock on 8 November 2018 worth over $99,999. On average, Alan trades about 8,402 units every 120 days since 2015. As of 8 November 2018 he still owns at least 423,366 units of Neos Therapeutics Inc stock.

You can see the complete history of Mr. Heller stock trades at the bottom of the page.

Alan Heller biography

Alan L. Heller serves as Independent Chairman of the Board of the Company. Mr. Heller has been an Operating Partner at Water Street Healthcare Partners, LLC, since January 2006. Mr. Heller was President and CEO of American Pharmaceutical Partners from October 2004 until November 2005, and prior to that was Corporate Vice President and President Global Renal at Baxter International from September 2000 until January 2004. Earlier, Mr. Heller served as President of Searle Operations at the time of its integration with Pharmacia Corporation. He currently serves as Chairman of the boards of directors of privately-held Capstone Development, Inc., Custopharm, Inc. and Long Grove Pharmaceuticals, LLC. Mr. Heller holds an M.B.A. from DePaul University and a B.S. from the University of Illinois, Chicago.

What is the salary of Alan Heller?

As the Independent Chairman of the Board of Neos Therapeutics Inc, the total compensation of Alan Heller at Neos Therapeutics Inc is $85,500. There are 3 executives at Neos Therapeutics Inc getting paid more, with Gerald McLaughlin having the highest compensation of $1,399,430.

How old is Alan Heller?

Alan Heller is 66, he's been the Independent Chairman of the Board of Neos Therapeutics Inc since 2009. There are no older and 9 younger executives at Neos Therapeutics Inc.

What's Alan Heller's mailing address?

Alan's mailing address filed with the SEC is 2940 N State Hwy 360 Service Rd E #400, Grand Prairie, TX 75050, USA.

Insiders trading at Neos Therapeutics Inc

Over the last 9 years, insiders at Neos Therapeutics Inc have traded over $796,275 worth of Neos Therapeutics Inc stock and bought 558,630 units worth $7,201,055 . The most active insiders traders include Jack W Schuler, James E Deerfield Mgmt L.P...., eBryant Fong. On average, Neos Therapeutics Inc executives and independent directors trade stock every 69 days with the average trade being worth of $42,698. The most recent stock trade was executed by Richard I Eisenstadt on 12 December 2018, trading 5,000 units of NEOS stock currently worth $10,800.

What does Neos Therapeutics Inc do?

Complete history of Mr. Heller stock trades at Neos Therapeutics Inc

Neos Therapeutics Inc executives and stock owners

Neos Therapeutics Inc executives and other stock owners filed with the SEC include:

• Gerald McLaughlin,
  President, Chief Executive Officer, Director
• Richard Eisenstadt,
  Chief Financial Officer, Treasurer
• John Limongelli,
  Senior Vice President, General Counsel and Corporate Secretary
• Alan Heller,
  Independent Chairman of the Board
• Linda Szyper,
  Independent Director
• John Schmid,
  Independent Director
• Gregory Robitaille,
  Independent Director
• Bryant Fong,
  Independent Director
• James Robinson,
  Independent Director
• Beth Hecht,
  Independent Director
• Vipin K Garg,
  President, CEO & Director
• Juergen Martens,
  Chief Tech/Operations Officer
• Thomas P Mc Donnell,
  Chief Commercial Officer
• Paul R Edick,
  Director
• Partners 2007, L.P.Presidio...,
  
• Dorothy Engelking,
  VP of Regulatory Affairs
• Mark Tengler,
  Chief Technology Officer
• Ralph Essex Capital Corp Ia...,
  
• Andrew G Delaware Street Ca...,
  
• Jack W Schuler,
  10% owner
• Venture Assoicates Ii Llcbu...,
  
• James E Deerfield Mgmt L.P....,